ReviewFrontiers in bioengineering and biotechnology2022
Organoid technology and applications in lung diseases: Models, mechanism research and therapy opportunities.
Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Deep Learning-Based Prediction of Epithelial Cytokine Responses for the Selection of Functionally Consistent Airway Organoids.Biomimetics (Basel, Switzerland) · 2026Article
- New approaches to uncover COPD pathobiology and develop therapies.JCI insight · 2026Review
- Research Advances and Disease Modeling in Respiratory Organoids.Biomedicines · 2026Review
- Lung organoids for respiratory diseases: overcoming translational hurdles in drug discovery and safety assessment.Frontiers in bioengineering and biotechnology · 2026Review
- A semi-automated algorithm for image analysis of respiratory organoids.PLoS computational biology · 2025Article
- Formulation Strategies for Immunomodulatory Natural Products in 3D Tumor Spheroids and Organoids: Current Challenges and Emerging Solutions.Pharmaceutics · 2025Review
- Modeling of lung organoid-based fibrosis for testing the sensitivity of anti-fibrotic drugs.Stem cell research & therapy · 2025Article
- Advances in the research and application of stem cell therapies for idiopathic pulmonary fibrosis.American journal of clinical and experimental immunology · 2025Review
- Review
- Unveiling the functional roles of patient-derived tumour organoids in assessing the tumour microenvironment and immunotherapy.Clinical and translational medicine · 2024Review
- Multiomic Investigations into Lung Health and Disease.Microorganisms · 2023Review
- NAFLD and AATD Are Two Diseases with Unbalanced Lipid Metabolism: Similarities and Differences.Biomedicines · 2023Review
- A deep learning model for drug screening and evaluation in bladder cancer organoids.Frontiers in oncology · 2023Article
- Mini-organs with big impact: Organoids in liver cancer studies.Oncology research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalency of lung disease has increased worldwide, especially in the aging population. It is essential to develop novel disease models, that are superior to traditional models. Organoids are three-dimensional (3D)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.